ZFIN ID: ZDB-FISH-150901-23930
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.
Fish name: i114Tg
Genotype: i114Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by i114Tg
Human Disease Conditions Citations
fungal infectious disease fungal treatment by injection: Mucor circinelloides Inglesfield et al., 2018
gastrointestinal system disease chemical treatment by environment: dextran sulfate Oehlers et al., 2017
chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Oehlers et al., 2017
GENE EXPRESSION
Gene expression in i114Tg
RNA expression
Expressed Gene Structure Conditions Figures
cd36 standard conditions Fig. 5 from Fink et al., 2015
cxcl8a chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
transection: caudal fin Fig. 1 from de Oliveira et al., 2015
Fig. 4 from Ogryzko et al., 2014
cxcl8b.1 chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
viral treatment by exposure to environment: Carp sprivivirus Fig. 1 from de Oliveira et al., 2015
defbl1 control Fig. 3 with image from Galindo-Villegas et al., 2012
germ free Fig. 3 with image from Galindo-Villegas et al., 2012
gbp4 control Fig. 1 from Tyrkalska et al., 2016
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
il1b control Fig. 1 from Tyrkalska et al., 2016
Fig. 3 with image from Galindo-Villegas et al., 2012
germ free Fig. 1 from Tyrkalska et al., 2016
Fig. 1 with image, Fig. 4 from Ogryzko et al., 2014
Fig. 3 with image from Galindo-Villegas et al., 2012
irf4a standard conditions Fig. 1 with image from Wang et al., 2015
lcp1 standard conditions Fig. 1 from Renshaw et al., 2006
lyz standard conditions Fig. 1 with image from Wang et al., 2015
mpeg1.1 standard conditions Fig. 1 from Benard et al., 2015
mpeg1.2 standard conditions Fig. 1 from Benard et al., 2015
mpx standard conditions Fig. 5 from Fink et al., 2015
Fig. 1 from Renshaw et al., 2006
nfil3 standard conditions Fig. 1 from Progatzky et al., 2012
ptgs2b transection: caudal fin Fig. 4 from Ogryzko et al., 2014
caiap bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 3 from Tyrkalska et al., 2017
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab2-lcp1 physical alteration: anatomical structure Fig. 6 from Varela et al., 2014
Fig. 1 with image from Jones et al., 2013
Ab1-lcp1 control Fig. 4 from Kanwal et al., 2013
Ab1-nitrotyrosine chemical treatment: pharmaceutical Fig. 4 with image from Elks et al., 2014
Ab1-nitrotyrosine bacterial treatment Fig. 1 with image, Fig. 2 with image, Fig. 3 with image, Fig. 4 with image, Fig. 5 with image from Elks et al., 2014
Fig. 3 with image, Fig. 7 from Elks et al., 2013
Ab1-gnb control Fig. 2 with image from Ke et al., 2017
Ab1-nitrotyrosine standard conditions Fig. 1 with image, Fig. 2 with image, Fig. 3 with image, Fig. 4 with image, Fig. 5 with image from Elks et al., 2014
Fig. 3 with image, Fig. 7 from Elks et al., 2013
Ab-2F11 control Fig. 3 from Lorent et al., 2015
Ab2-nos standard conditions Fig. 1 with image from Elks et al., 2014
Fig. 5 with image from Elks et al., 2013
Ab2-nos bacterial treatment Fig. 1 with image from Elks et al., 2014
Ab2-lcp1 standard conditions Fig. 6 from Varela et al., 2014
Fig. S1 with image from Jones et al., 2013
Ab-2F11 chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
Ab1-gnb1a control Fig. 2 with image from Ke et al., 2017
Ab4-GFP GFP control Fig. 2 with image from Hedrera et al., 2013
Reporter gene expression
Expressed Gene Structure Conditions Figures
DsRed amputation: caudal fin Fig. 1, Fig. 3, Fig. 4 from de Oliveira et al., 2015
EGFP standard conditions Fig. S8 with image from Tyrkalska et al., 2016
Fig. 4 from Stachura et al., 2013
transection: caudal fin Fig. 6 with image from Robertson et al., 2016
GFP standard conditions 49 figures with image from 30 publications
chemical treatment: pharmaceutical 11 figures with image from 9 publications
bacterial treatment 49 figures with image from 24 publications
PHENOTYPE
Phenotype in i114Tg
Phenotype Conditions Figures
acute inflammatory response increased occurrence, abnormal chemical treatment: copper(II) sulfate Fig. 3 with image from Gallardo et al., 2015
gall bladder morphology, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
gill neutrophil amount, ameliorated chemical treatment: environmental contaminant Fig. 4 from Progatzky et al., 2016
gill neutrophil decreased amount, abnormal chemical treatment: environmental contaminant Fig. 3, Fig. 4 from Progatzky et al., 2016
heart leukocyte activation increased occurrence, abnormal chemical treatment by environment: isoprenaline Fig. 6 from Kossack et al., 2017
heart neutrophil increased amount, abnormal chemical treatment by environment: isoprenaline Fig. 6 from Kossack et al., 2017
hindbrain macrophage decreased amount, abnormal fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone Fig. 2 from Inglesfield et al., 2018
hindbrain neutrophil decreased amount, abnormal fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone Fig. 2 from Inglesfield et al., 2018
hindbrain neutrophil increased amount, abnormal fungal treatment by injection: Mucor circinelloides Fig. 2 with image from Voelz et al., 2015
intestine anatomical region has extra parts of type neutrophil, abnormal bacterial treatment: Escherichia coli O157:H7 Fig. 3 with image from Stones et al., 2017
intestine neutrophil amount, ameliorated chemical treatment by diet: glycoprotein, protein content Fig. 1 with image from Ulloa et al., 2016
intestine neutrophil amount, ameliorated chemical treatment by environment: cabergoline, chemical treatment by environment: dextran sulfate Fig. 2 from Oehlers et al., 2017
intestine neutrophil amount, ameliorated chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid, chemical treatment by environment: cabergoline Fig. 2 from Oehlers et al., 2017
intestine neutrophil amount, ameliorated chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid, chemical treatment by environment: sincalide Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, abnormal chemical treatment by environment: dextran sulfate, chemical treatment by environment: sincalide Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, abnormal chemical treatment by environment: dextran sulfate Fig. 2, Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, abnormal chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 1, Fig. 2, Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, abnormal chemical treatment by diet: glycoprotein, protein content Fig. 1 with image from Ulloa et al., 2016
intestine neutrophil increased amount, exacerbated chemical treatment by environment: haloperidol, chemical treatment by environment: dextran sulfate Fig. 2 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: lorglumide Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: dextran sulfate, chemical treatment by environment: devazepide Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: devazepide, chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: lorglumide, chemical treatment by environment: dextran sulfate, chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 3 from Oehlers et al., 2017
leukocyte il1b expression amount, ameliorated transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 4 from Ogryzko et al., 2014
leukocyte il1b expression amount, ameliorated transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 4 from Ogryzko et al., 2014
leukocyte il1b expression increased amount, abnormal transection: caudal fin Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal transection: caudal fin Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal transection: caudal fin Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 4 from Ogryzko et al., 2014
leukocyte protein nitrosylation increased process quality, abnormal bacterial treatment Fig. 3 with image, Fig. 7 from Elks et al., 2013
leukocyte migration involved in inflammatory response process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 3, Fig. 5, Fig. 6 from Burgon et al., 2014
leukocyte migration involved in inflammatory response process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 6 from Burgon et al., 2014
leukocyte migration involved in inflammatory response process quality, abnormal physical alteration: caudal fin, chemical treatment: pharmaceutical Fig. 7 from de Oliveira et al., 2013
macrophage accumulation liver and biliary system, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
macrophage decreased amount, abnormal viral treatment: Carp sprivivirus Fig. 6 from Varela et al., 2014
neutrophil accumulation swim bladder, abnormal fungal treatment by injection: Mucor circinelloides Fig. 5 with image from Voelz et al., 2015
neutrophil accumulation liver and biliary system, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
neutrophil amount, normal bacterial treatment by exposure to environment: Pseudomonas aeruginosa Fig. 1 with image from Díaz-Pascual et al., 2017
neutrophil decreased amount, abnormal bacterial treatment by injection: Burkholderia cenocepacia Fig. 3 with image from Mesureur et al., 2017
neutrophil decreased speed, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 6 from Burgon et al., 2014
neutrophil decreased speed, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 4, Fig. 6 from Burgon et al., 2014
neutrophil caiap expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 3 from Tyrkalska et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Escherichia coli DH5[alpha] Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Burkholderia stabilis Fig. 3 with image from Mesureur et al., 2017
neutrophil increased amount, abnormal fungal treatment by injection: Mucor circinelloides Fig. 1 from Inglesfield et al., 2018
neutrophil il1b expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
neutrophil increased amount, abnormal chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 1 from Oehlers et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Burkholderia cenocepacia Fig. 7 with image from Mesureur et al., 2017
neutrophil normal amount, normal chemical treatment: pharmaceutical Fig. 3 with image from Herbst et al., 2015
neutrophil apoptotic process increased process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 3 from Burgon et al., 2014
neutrophil apoptotic process increased occurrence, abnormal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 3 with image from Hoodless et al., 2016
neutrophil apoptotic process occurrence, normal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 3 with image from Hoodless et al., 2016
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: SB220025, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: anthra[1,9-cd]pyrazol-6(2H)-one, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: 2-(2-amino-3-methoxyphenyl)chromen-4-one, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: wortmannin, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: PP2, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 2 from Ogryzko et al., 2014
neutrophil chemotaxis decreased occurrence, abnormal transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 2 from Ogryzko et al., 2014
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil chemotaxis decreased process quality, abnormal amputation: caudal fin, chemical treatment: dibenziodolium chloride Fig. 2 from de Oliveira et al., 2014
neutrophil chemotaxis decreased process quality, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil chemotaxis increased occurrence, abnormal bacterial treatment: Escherichia coli O157:H7 Fig. 3 with image from Stones et al., 2017
neutrophil chemotaxis increased occurrence, abnormal bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil chemotaxis increased occurrence, abnormal bacterial treatment by injection: Escherichia coli DH5[alpha] Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil mediated killing of fungus process quality, normal fungal treatment by injection: Candida albicans Fig. 2 from Brothers et al., 2011
neutrophil migration decreased occurrence, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil migration decreased process quality, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil migration decreased process quality, abnormal transection: caudal fin, chemical treatment by environment: isopimpinellin Fig. 2 with image from Robertson et al., 2016
neutrophil migration process quality, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil migration process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 6 from Burgon et al., 2014
neutrophil migration process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 3, Fig. 4, Fig. 5, Fig. 6 from Burgon et al., 2014
neutrophil migration process quality, normal bacterial treatment by exposure to environment: Pseudomonas aeruginosa Fig. 1 with image from Díaz-Pascual et al., 2017
notochord neutrophil increased amount, abnormal bacterial treatment by injection: Escherichia coli K-12 Fig. 7 with image from Nguyen-Chi et al., 2014
phagocytosis process quality, normal fungal treatment by injection: Candida albicans Fig. 2 from Brothers et al., 2011
regenerating fin neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 2 with image, Fig. 7 with image from Hoodless et al., 2016
regenerating fin neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by environment: alvocidib Fig. 2 with image from Hoodless et al., 2016
regenerating fin neutrophil chemotaxis occurrence, normal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 2 with image from Hoodless et al., 2016
regenerating fin neutrophil chemotaxis occurrence, normal transection: caudal fin, chemical treatment by environment: alvocidib Fig. 2 with image from Hoodless et al., 2016
regeneration epithelium neutrophil decreased amount, abnormal transection: caudal fin Fig. 6 with image from Robertson et al., 2016
regeneration epithelium neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by injection: nedocromil Fig. 6 with image from Robertson et al., 2016
regeneration epithelium neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by environment: isopimpinellin Fig. 2 with image, Fig. 3 with image from Robertson et al., 2016
skeletal muscle neutrophil increased amount, abnormal viral treatment by injection: unidentified influenza virus Fig. 4 with image from Goody et al., 2017
skeletal muscle cell degenerate, abnormal viral treatment by injection: unidentified influenza virus Fig. 4 with image from Goody et al., 2017
skeletal muscle cell detached from skeletal muscle cell, abnormal viral treatment by injection: unidentified influenza virus Fig. 4 with image from Goody et al., 2017
trunk neutrophil increased amount, abnormal chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 1 from Oehlers et al., 2017
whole organism decreased life span, abnormal fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone Fig. 2 from Inglesfield et al., 2018
whole organism gbp4 expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
whole organism cxcl8b.1 expression increased amount, abnormal chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8b.1 expression increased amount, abnormal chemical treatment by environment: poly(I:C) Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8b.1 expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8b.1 expression increased amount, abnormal viral treatment by exposure to environment: Carp sprivivirus Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal chemical treatment by environment: poly(I:C) Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal viral treatment by exposure to environment: Carp sprivivirus Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from de Oliveira et al., 2015
whole organism il1b expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
whole organism neutrophil amount, normal transection: caudal fin, chemical treatment by environment: alvocidib Fig. 2 with image from Hoodless et al., 2016
whole organism neutrophil amount, normal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 2 with image from Hoodless et al., 2016

CITATIONS  (123)